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Abstract
According to the “gain-of-toxicity mechanism”, neuronal loss during cerebral proteinopathies is caused by
accumulation of aggregation-prone conformers of misfolded cellular proteins, although it is still debated which
aggregation state actually corresponds to the neurotoxic entity. Autophagy, originally described as a variant of
programmed cell death, is now emerging as a crucial mechanism for cell survival in response to a variety of cell
stressors, including nutrient deprivation, damage of cytoplasmic organelles, or accumulation of misfolded proteins.
Impairment of autophagic flux in neurons often associates with neurodegeneration during cerebral amyloidosis,
suggesting a role in clearing neurons from aggregation-prone misfolded proteins. Thus, autophagy may represent a
target for innovative therapies. In this work, we show that alterations of autophagy progression occur in neurons
following in vitro exposure to the amyloidogenic and neurotoxic prion protein-derived peptide PrP90-231. We report
that the increase of autophagic flux represents a strategy adopted by neurons to survive the intracellular accumulation
of misfolded PrP90-231. In particular, PrP90-231 internalization in A1 murine mesencephalic neurons occurs in acidic
structures, showing electron microscopy hallmarks of autophagosomes and autophagolysosomes. However, these
structures do not undergo resolution and accumulate in cytosol, suggesting that, in the presence of PrP90-231,
autophagy is activated but its progression is impaired; the inability to clear PrP90-231 via autophagy induces
cytotoxicity, causing impairment of lysosomal integrity and cytosolic diffusion of hydrolytic enzymes. Conversely, the
induction of autophagy by pharmacological blockade of mTOR kinase or trophic factor deprivation restored
autophagy resolution, reducing intracellular PrP90-231 accumulation and neuronal death. Taken together, these data
indicate that PrP90-231 internalization induces an autophagic defensive response in A1 neurons, although incomplete
and insufficient to grant survival; the pharmacological enhancement of this process exerts neuroprotection favoring
the clearing of the internalized peptide and could represents a promising neuroprotective tool for neurodegenerative
proteinopathies.
Introduction
Protein misfolding is the main pathogenic event
responsible for synaptic loss, neuronal death, and gliosis
during all neurodegenerative disorders1–4. In particular,
β-amyloid (Aβ) peptides, which are organized as insoluble
amorphous aggregates or amyloid fibrils, and plaques
accumulate in Alzheimer's disease (AD) patient brains5,
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while pathognomonic for Parkinson's disease (PD) is
intraneuronal aggregates of α-synuclein6. Prion diseases
(transmissible spongiform encephalopathies, TSE) are
recognized with the pathogenetic mechanism of protein
misfolding of the prion protein (PrP), which shifts from a
physiological conformation (PrPC) into a protease-resis-
tant, amyloidogenic isoform, named PrP “scrapie”
(PrPSc)7–9. In TSE patients, PrPSc oligomeric aggregates
have been identified in brain areas displaying neuron
degeneration, vacuolization, and glial activation10–12,
suggesting that during PrPC=> PrPSc transition
neurotoxic species are generated before amyloid fibrillo-
genesis13–16. Similarly, during AD-associated neurode-
generation, Aβ1–42 is recovered as intraneuronal
aggregates in brain areas where neuronal death is parti-
cularly significant17, anticipating amyloid deposition18. It
was proposed that the state of aggregation of all misfolded
peptides determines their neurotoxicity, oligomers being
more effective in reducing neuron viability in vitro19,20
and cognitive ability in vivo21,22. Thus, neurotoxicity
seems independent from the nature or function of native
proteins, but caused by the increased hydrophobicity of
oligomers23–25. In this view, all amyloidogenic polypep-
tides (PrPSc, Aβ, and α-synuclein) share common
neurodegenerative mechanisms3,26, via oligomers’ inter-
action with neuronal targets22,27–29, making protein mis-
folding and aggregation process a valuable target for
disease-modifying therapies against neurodegenerative
proteinopathies30.
Eukaryotic cells perform a tight quality control of pro-
tein synthesis to eliminate misfolded proteins2. Ubiquitin-
proteasome and lysosome-mediated autophagy are the
most relevant protein homeostasis systems31. Originally
described as mechanism of programmed cell death,
autophagy is a crucial strategy to overcome harmful
conditions by recycling nutrient material. Double-
membrane vesicles (autophagosomes) engulf altered
proteins and organelles before receiving the hydrolytic
contribution of lysosomes, thereby assuming the name of
autolysosomes32. Autolysosome content is then digested
and recycled in the cytoplasm through active transport.
Thus, autophagy may prevent cell death during nutrient
deprivation by allowing recycling of proteins until the
energetic supply is restored33. Autophagosomes can also
digest damaged mitochondria or aggregated proteins34,35,
which is a critical activitiy to prevent lysosomal- and
mitochondrial-dependent apoptosis, and to reduce the
intracellular burden of unwanted protein36,37. Indeed,
impairment of autophagy causes neuronal death during
normal aging, AD, PD, and TSEs38–41. Pharmacological
induction of autophagy by rapamycin, valproic acid, or
lithium, favors the degradation of aggregation-prone
proteins, delaying the clinical onset or reducing the
symptoms in animal models of proteinopathies41,42.
We report the role of autophagy as a response to the
neurotoxic effects of intracellular aggregation of a mis-
folded prion peptide, evaluating autophagy enhancers as
neuroprotective agents. PrPSc neurotoxicity was modeled
using a recombinant peptide matching the
90–231 sequence of human PrPC43, which corresponds to
a protease-insensitive C-terminal fragment of PrPSc
detected in TSE patients44. By controlled thermal dena-
turation, PrP90-231 β-sheet content increases (up to
58.8%)45 through interferences with determinants of helix
formation46. β-sheet-rich PrP90-231, showing high
hydrophobicity, and resistance to proteolysis, is organized
as soluble oligomers, which, after prolonged denaturation,
become insoluble and, eventually, amyloid fibrils47.
PrP90-231 oligomers are neurotoxic in vitro45,47 with
similar efficacy than brain-purified PrPSc48,49. PrP90-231
neurotoxicity is dependent on intracellular accumulation,
as insoluble aggregates cause lysosome destabilization50,51
and cytosolic diffusion of cathepsin D (Cat-D)51.
The vesicular accumulation of aggregated PrP90-231
poses the following questions about the finalistic role of
its intracellular partition: (1) is it cause of cell death
through the impairment of lysosomal-mediated protein
homeostasis (2) or does it represent a cell attempt to
neutralize the peptide through autophagic proteolysis?
Here we demonstrate that PrP90-231 increases the
formation of PrP90-231-containing autophagolysosomes,
but the increased autophagy does not proceed toward
resolution and does not prevent neuronal death; con-
versely, pharmacological activation of autophagy favors
aggregate clearing and counteracted PrP90-231 toxicity.
Thus autophagy represents a neuronal defensive strategy
against intracellular aggregation of misfolded PrP90-231,
and its pharmacological enhancement is a possible ther-
apeutic goal in neurodegenerative conditions.
Results
PrP90-231 induces toxicity of A1 neurons
Misfolded PrP90-231 causes apoptosis in neurons via
direct interaction27,28,51, or through astrocytic and
microglial production of prostaglandins, cyto/chemo-
kines, and nitric oxide52–54.
Here we used, as neuronal model, A1 immortalized
murine mesencephalic neuronal cell line, which combines
neuronal phenotype and indefinite in vitro proliferation54.
SYTOX green staining measured by flow cytometry
showed that 48 h PrP90-231 treatment reduced A1 via-
bility up to 41% (Fig. 1a). PrP90-231 neurotoxicity was
time- and concentration-dependent, as shown by Trypan
blue exclusion test, in which the percentage of surviving
cells decreased from 90% (controls) to 75 and 60%, after
48 h exposure to 1 and 5 μM PrP90-231, respectively, and
to 40 and 23%, after 72 h of treatment (Fig. 1b). Fur-
thermore, we measured A1 cell viability by MTT assay
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after 72 h, with PrP90-231 concentrations (0.1–10 μM),
which induced a concentration-dependent cell death
(Fig. 1c). These results were confirmed by analyzing, by
phase-contrast imaging, the A1 cultures after 2 and 4 days





























































































Fig. 1 PrP90-231 induces A1 neuron death. a Flow cytometry analysis of cell death. Dead cells in the culture were quantified after 24 and 48 h of
treatment with PBS (vehicle) or PrP90-231 (100 and 500 nM), by measuring the percent of cells that incorporate SYTOX green. * P < 0.05 vs. vehicle. b
Cell viability was quantified in control cells after 48 and 72 h (treatment with PBS, 0 on abscissae) or PrP90-231 (1 and 5 μM) measuring the percent of
live cells by Trypan blue exclusion test. *P < 0.05 and **P < 0.01 vs. PBS. c Mitochondrial viability of A1 cells was evaluated by MTT-reduction assay
after 72 h of treatment with PBS (0 on abscissae) and PrP90-231 at concentrations ranging from 0.1 to 10 μM. *P < 0.05 and **P < 0.01 vs. PBS. d Phase-
contrast pictures of A1 cells that have been treated with PrP90-231 5 μM for two (middle panel) and four (lower panel) days in comparison with
untreated (upper panel). Images has been acquired with C- plan 10 × /0.22 magnification lens. Bar 100 μm. All the data are reported as mean + /−
SEM of three independent experiments each performed in quadruplicate
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PrP90-231 is internalized into acidic vesicles
To test whether vesicular accumulation of proteolysis-
resistant aggregates of misfolded PrP90-231 promotes cell
death via impairment of lysosomal stability or represents a
neuronal attempt to sequester and eliminate the cytotoxic
peptide, we assessed the ability of A1 neurons to inter-
nalize PrP90-231 and activate lysosomal/autophagic pro-
teolytic pathways. First, we measured the presence of
detergent-insoluble PrP90-231 within A1 cytosol, after
1–48 h of exposure to the peptide. We observed by
immunoblotting that PrP90-231 content (16 kDa,
3F4-immunoreactive band, Fig. 2a) gradually increased
during the treatment. To localize PrP90-231 within A1
cytoplasmic structures, we evaluated the intracellular
accumulation of the peptide by immunogold transmis-
sionelectron microscopy (TEM) (Fig. 2b), indirect fluor-
escence (Fig. 2c), and western blot of lysosomal crude
fraction (Fig. 2d). Immunostaining was performed
using the polyclonal antibody FL253 that recognizes
both endogenous PrPC and PrP90-231, instead of mono-
clonal 3F4, because the sequence 109-111, specifically
recognized by 3F4 antibody might be buried inside PrP90-
231 aggregates. In untreated cells, FL253 diffusely stains
the cytoplasm without detectable protein clustering
(Fig. 2c, left panel), whereas PrP90-231 treatment induced
the formation of large aggregates (Fig. 2c, right panel),
confirming that PrP90-231 is internalized in subcellular
structures, possibly overloading the vesicular compart-
ment. This hypothesis was supported by immunogold/
TEM analysis, showing increased number of electron-
dense vesicles containing PrP90-231 immunoreactivity
(Fig. 2b). Since PrP90-231 amino acid sequence overlaps
endogenous PrPC and both are recognized by FL236, to
define the source of the immunoreactive clusters observed
in PrP90-231-treated cells, we performed a semi-
quantitative analysis of PrP90-231 accumulation by
immunoblotting, analyzing its distribution between vesi-
cular and cytosolic fractions. Here, we used the 3F4
antibody that does not react with the murine (endogen-
ous) PrPC. A 16 kDa 3F4-reactive band was observed only
in the vesicular fraction of PrP90-231-treated cells (1 μM,
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Fig. 2 PrP90-231 internalization in A1 neurons. a Time-dependent internalization of detergent-insoluble PrP90-231: detergent-insoluble fraction
from A1 cells treated for 1, 2, 6, 24, and 48 h with PrP90-231 (1 μM) was extracted and separated by centrifugation; immunoblotting was performed
with the 3F4anti-PrP antibody, loading 10 μg protein/lane. Anti-α-tubulin antibody was used to normalize protein loading between lanes.
Immunoreactivity for 3F4 antibody revealed a 16 kDa immunoreactive band reaching a maximum intensity after 24 h of treatment with PrP90-231. b
Immunogold electron microscopy for PrP90-231 intracellular aggregates in A1 neurons treated for 48 h with PrP90-231 (1 μM). Immunogold labeling
of anti-PrP antibody FL253 revealed the presence of PrP-immunoreactive signals entrapped into electron-dense vesicles. Space bar 500 nm. c Indirect
immunostaining with anti-PrP antibody FL235 of A1 cells after 48 h of treatment with PBS (left) or PrP90-231 (1 μM) (right). The exposure to PrP90-231
stimulates the appearance of fl235-immunoreactive spheroidal aggregates; images has been acquired with HCX Fluotar PL 40×/0,75 magnification
lens. Bar: 25 μm. d Detection by immunoblotting of PrP90-231 in vesicular and cytosolic fraction of A1 cells after 48 h of treatment with PBS or PrP90-
231 (1 μM). Immunoreactivity for anti-PrP antibody 3F4 shows the appearance of a 16 kDa band in vesicular fraction only. Immunoreactivity for α-
tubulin (lower blot) has also been detected to ascertain that equal amount of protein has been loaded between treated and untreated samples. All
the data reported are representative of three independent experiments
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PrP90-231 triggers lysosomal and mitochondrial
destabilization
The relevance of lysosomal impairment in PrP90-231
toxicity was analyzed by measuring the effects of PrP90-
231 on the expression and cytosol diffusion of Cat-D. We
measured, using the confocal microscopy, the number
and size of acidic vesicles by A1 neuron labeled with
lysotracker red DND-99 (Fig. 3a). While most of the
control neurons showed fewer number of lysotracker red-
positive vesicles, but after PrP90-231 treatment, a high
number of enlarged structures were stained. Since lyso-
tracker red cannot discriminate between lysosomes and
autophagosomes, but its fluorescence intensity increases
in autophagolysosomes55, the above results pose the
intriguing question whether the high number of lyso-
tracker red-positive vesicles in treated neurons derived
from impairment of autophagic resolution after PrP90-
231 accumulation, or it represents the activation of pro-
tective mechanisms aimed to eliminate misfolded PrP90-
231.
To demonstrate that PrP90-231 causes activation of
lysosomal proteolytic activity, by altering lysosomal per-
meability, we analyzed the expression and the cytoplasmic
distribution of the lysosomal protease Cat-D by immu-
nocytofluorescence and immunoblotting. In basal condi-
tions, Cat-D was detectable as small round bodies
scattered through the cytoplasm or localized in the
perinuclear region (Fig. 3b), while after PrP90-231 treat-
ment, a strong diffuse Cat-D immunoreactivity was
observed throughout the cytosol. Semi-quantitative eva-
luation of Cat-D expression and localization was per-
formed by immunoblotting in lysosomal and cytosolic
crude protein fractions by using antibody that detects the
cleaved (active) form of the enzyme (Fig. 3d). Vesicular
(lysosomal) and cytosolic crude fractions were separated
by differential centrifugation from control and PrP90-
231-treated A1. While no significant immunoreactivity
was observed in both fractions of control cells, indicating
low Cat-D activity, in PrP90-231-treated cells, cleaved
Cat-D (37 kDa immunoreactive band) was detected in
both lysosomal and cytosolic fractions. Thus the treat-
ment with PrP90-231 induces the activation of Cat-D and
causes its cytosolic diffusion. Cat-D diffusion is respon-
sible for mitochondrial depolarization56 and initiates
caspase-dependent apoptosis. Consequently, we measured
mitochondrial membrane depolarization in A1 neurons
treated with PrP90-231, using the JC-1 fluorescent probe,
which accumulates into mitochondria exhibiting orange/
red to green fluorescence shift, upon the loss of mito-
chondria transmembrane potential. Figure 3c depicts live
cell imaging of A1 mitochondria after treatment with
vehicle or PrP90-231. PrP90-231 treatment produced a
marked reduction of red/orange fluorescence of JC-1,
















Fig. 3 PrP90-231 alters lysosomal permeability and
mitochondrial potential. a Live cell imaging of acidic vesicles in
A1 cells. Cells were grown on glass bottom petri dishes and treated
with PBS (cont) and PrP90-231 (1 μM). After 24 h, cells were loaded with
acidophilic dye LysoTracker Red DND-22 and observed in confocal
microscopy (Scale bar: 25 μm. b PrP90-231 increases the expression and
cytosolic diffusion of Cat-D in A1 cells. After 48 h of treatment with PBS
(cont) and PrP90-231 1 μM, cells were immunostained with anti-Cat-D
and observed under inverted fluorescent microscope using
magnification lens APO Plan 60 × 1,40 oil. (Scale bar: 25 μm). c PrP90-
231 triggers A1 mitochondrial depolarization. Cells were grown on glass
bottom petri dishes and treated with PBS (cont) and PrP90-231 1 μM.
After 24 h, cells were loaded with mitochondrial potential sensor JC-1
and observed in confocal microscopy. The exposure to the peptide
induces a red to green shift of JC-1 fluorescence. Scale bar: 25 μm. d
Detection by immunoblotting of Cat-D expression in vesicular (ves) and
cytosolic (cyt) crude fractions in A1 cells after 48 days of treatment with
PBS (cont) and PrP90-231 (1 μM). The treatment with PrP90-231 caused
a strong increase of Cat-D expression and a detectable diffusion into
the cytosolic fraction. All the data reported are representative of three
independent experiments
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neurons react to PrP90-231 intracellular accumulation
with its segregation within lysosomes, resulting in a strong
activation of the proteolytic machinery, followed by Cat-D
cytosolic diffusion, and mitochondrial destabilization. The
persistence of PrP90-231 aggregates within cells and the
prolonged activation of hydrolytic enzymes are critical for
PrP90-231 to impair the cell survival.
PrP90-231 impairs autophagy progression in A1 cells
As autophagy is a neuronal survival strategy by
removing damaged organelles and degrading protein
aggregates, we tested whether lysosome damage by
PrP90-231 causes neurotoxicity because of impaired
autophagy machinery. A1 neurons are resistant to serum
deprivation (data not shown), indicating that these cells
are able to activate autophagy-dependent recycle of
nutrients, and that the progression of autophagy flux
represents a crucial mechanism of protection from cyto-
toxic insults. We measured autophagy flux in basal con-
ditions, after impairment of cytoplasmic homeostasis, or
PrP90-231 treatment (Fig. 4a). The expression of
autophagosome-related protein LC3B57 was evaluated by
immunoblotting in A1 neurons deprived of trophic fac-
tors for 0.5–6 h (Fig. 4b) or treated with rapamycin for
2–48 h (Fig. 4c), showing that both conditions increased
the accumulation of the 14 KDa form of LC3B (LC3BII),
associated with the elongation phase of autophagosomes
index of autophagy activation. Also, PrP90-231 treatment
(1 μM, for 24–48 h) induced LC3B-II expression, sug-
gesting that intraneuronal accumulation of PrP90-231,
besides interfering with lysosomal activity, produces per-
turbations of the autophagic flux (Fig. 4d). TEM mor-
phological analysis of A1 cells, performed to assess the
presence of autophagy-related organelles after trophic
factors withdrawal or rapamycin treatments, evidenced
high number of double-membrane autophagosomes that,
although present in basal conditions, are significantly
increased by all the treatments (Fig. 4a). PrP90-231 (24 h,
1 µM) highly increased the number of autophagic vesicles,
although mainly as single-membrane organelles (autop-
hagolysosomes) filled with electron-dense material, sug-
gesting the occurrence of qualitative differences between
the autophagic flux induced by the peptide and the other
stimuli. LC3B-II immunoblotting performed in A1 neu-
rons after co-treatment with PrP90-231 and rapamycin
(Fig. 4e) showed an additive induction of LC3B-II
expression mainly in the presence of low PrP90-231
concentration (1 μM) but not when higher concentrations
(10 μM) were used, likely due to the saturation of A1
capacity to activate autophagic flow.
LC3B-II expression could be also increased when
impaired resolution of autophagolysosomes occurs, as
possibly caused by the protease-resistance of PrP90-231.
Thus, we investigated whether PrP90-231 treatment
interfere with autophagic flux progression, by measuring
the expression of the autophagy-adaptor protein p62,
which drives cytoplasmic material into autophagosomes
and is physiologically digested when autophagosomes fuse
with lysosomes58. Thus, increased p62 levels are a bio-
chemical hallmark of autophagy blockade59,60 and are
observed during normal aging or proteinopathies. PrP90-
231 treatment time-dependently increased p62 content,
with a plateau after 24 h (Fig. 5a,b). These results indicate
that autophagy is induced by PrP90-231 but an impair-
ment of the final autophagolysosomes resolution occurs.
Importantly, in the presence of rapamycin, p62 increase
induced by PrP90-231 was almost completely abolished.
Similarly, analyzing the content of autophagy-related
vesicles by TEM, we show an inverse ratio between
early and late autophagosomes according to the treat-
ments, with the latter that are accumulated in PrP90-231-
treated cells and reduced in the presence of rapamycin
(Fig. 5c,d). Thus, we propose that autophagy boost
induced by rapamycin can overcome autophagy impair-
ment induced by PrP90-231.
Activation of autophagy reduces the amount of
internalized PrP90-231
To test whether rapamycin restores autophagy resolu-
tion in PrP90-231-treated cells, we analyze A1 neurons by
immunogold TEM for PrP90-231 vesicular accumulation,
in the absence or presence of rapamycin (Fig. 6a).
Immunogold TEM allowed the determination of the
number of autophagic structures containing PrP immu-
noreactivity (calculated as ratio between the number of
immunogold-positive spots and the area of each autop-
hagic structure). We observed that the number of
autophagic vesicles containing PrP90-231 were lower in
cells co-treated with rapamycin in comparison with neu-
rons receiving PrP90-231 only (Fig. 6a). Furthermore, the
amount of PrP90-231 (16 KDa 3F4-immunoreactive band)
in the lysosomal fraction was significantly reduced after
co-treatment with rapamycin (Fig. 6b,c). These results
suggest that the activation of autophagy induced by
rapamycin significantly reduces the intracellular accu-
mulation of PrP90-231, likely favoring its clearing by
autophagy. Thus, the accumulation of PrP90-231 inso-
luble aggregates induces autophagic response in neurons
but, as its resolution is impaired by insolubility and pro-
tease resistance, it results in Cat-D diffusion in the
cytosol and apoptosis. In the presence of rapamycin, the
lower amounts of vesicular PrP90-231 and a complete
autophagic flux suggest that proper progression of
autophagy causes PrP90-231 digestion, prevents alteration
of autophagolysosomal membranes, and favors neuron
survival.
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Induction of autophagy protects A1 cells from PrP90-231
toxicity
To demonstrate that autophagy resolution prevents
neurotoxicity, we measured A1 viability after PrP90-231
treatment in conditions that promote autophagy. To elicit
physiological or pharmacological activation of autophagy,
A1 neurons were deprived from trophic factors for 24 h,
or treated with rapamycin or valproic acid before PrP90-
231 treatment. Using MTT-reduction assay, we show that
the concentration-dependent cytotoxicity of PrP90-231
(0.1–10 μM, for 72 h) was significantly counteracted,
although not abolished in serum-deprived or rapamycin-
treated A1 neurons (Fig. 7a). Noteworthy, the protective
effect of serum withdrawal and rapamycin were depen-
dent on PrP90-231 concentration, being highly significant
for concentration between 1 and 3 μM, and less effective
for lower (0.1–0.3 μM) or higher (10 μM) concentrations.
Similarly, autophagy activation by valproic acid (1 mM)61
antagonized PrP90-231 neurotoxicity (Fig. 7b). To
demonstrate that rapamycin neuroprotection is depen-
dent on autophagy enhancement, we tested its activity in
experimental conditions in which autophagy was already
induced. First, we tested whether rapamycin and valproic
acid protection was additive, showing that the combina-
tion of the two drugs matched perfectly the effects
induced by the individual agents (Fig. 7b). Then, A1
neurons were exposed to PrP90-231, with or without
rapamycin, after 24 h of growth in standard medium
(STD) or trophic factor withdrawal (serum-deprived
cells); cell viability was evaluated after further 48 h
(Fig. 7c). PrP90-231 neurotoxicity was reduced in cells
grown in conditions of nutrient deprivation (Fig. 7a), but
not further protection was observed in the presence of
rapamycin (Fig. 7c), which, otherwise, antagonized PrP90-
A
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Fig. 4 Trophic factor deprivation, rapamycin and PrP90-231 increase the number of autophagosomes. a Morphological analysis of A1
cytoplasm by electron microscopy after trophic factors withdrawal (serum deprivation), treatment with rapamycin 10 nm and PrP90-231 1 µM for 24
h. Images evidenced that serum deprivation and the treatment with both rapamycin and PrP90-231 induced appreciable increase of double-
membrane autophagosomes, along with autophagolysosomes, containing electron-dense material (arrows). Space bar: 200 nm. Evaluation by
immunoblotting of the time-dependent expression of LC3I-II after trophic factors withdrawal (b), rapamycin (10 nM) (c), PrP90-231 (1 μM) (d), and
PrP90-231 (1 and 10 μM) in the absence or the presence of rapamycin (10 nM) (e). The amount of autophagosome-bound 14 kDa form of LC3B
(LC3BII) was quantified by densitometry (histograms below each blot) and expressed as ratios on α-tubulin expression. LC3BII/α-tubulin values were
expressed as percent of time 0 from three separate experiments. PrP90-231, trophic factor withdrawal, and rapamycin induced significant increase in
LC3BII. *P < 0.05 and **P < 0.01 vs. time 0. Additive effects of rapamycin on increasing LC3II formation are appreciable only on PrP90-231 (1 μM). **P <
0.01 vs. cont; °P < 0.05 vs. PrP90-231. All the data are reported as mean+/− SEM of three independent experiments each performed in quadruplicate
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231 in standard culture conditions (Fig. 7c, left columns).
Moreover, rapamycin protection against PrP90-231 neu-
rotoxicity was abolished by autophagy inhibition induced
by 3-methyladenine (3-MA)57 (Fig. 8a). Conversely, the
blockade of autophagic response by 3-MA did not affect
PrP90-231 toxicity (not shown), confirming that the
increased autophagy occurring in these conditions was
not causally related to PrP90-231 neurotoxicity but
represents a tentative to eliminate the misfolded peptide.
Thus, rapamycin does not induce additive neuroprotec-
tion when autophagy is already activated (as occurs after
valproic acid addition or growth factor starvation), while
its effects are abolished when autophagy is pharmacolo-
gically blocked. Conversely, when A1 neurotoxicity was
induced through different pathways such as oxidative
stress caused by hydrogen peroxide (H2O2, 200 μM),
rapamycin was completely ineffective, while neuronal
death was prevented in the presence of the antioxidant
reduced glutathione (GSH)62 (Fig. 8b). Similarly,
rapamycin did not protect from cell death induced by
nitric oxide radicals (sodium nitroprussiate treatment) or
by excitotoxicty (by glutamic acid) (data not shown).
These data suggest that neuroprotective effects of rapa-
mycin are mediated only by increasing autophagy, mainly
when this mechanism is impaired by misfolded peptides,
without significant autophagy-independent effects. How-
ever, while the activation of autophagy by rapamycin,
valproic acid, or serum deprivation is the main mechan-
ism of protection against PrP90-231 neurotoxicity, these
treatments did not completely abolish PrP90-231-
dependent cell death, suggesting that different
autophagy-insensitive mechanisms are involved in PrP90-
231 neurotoxicity, which, in part, might involve ROS
accumulation caused by mitochondrial dysfunction. In
fact, GSH treatment, slightly, but statistically significantly,
protected A1 neurons from PrP90-231 toxicity (Fig. 8b),
indicating that ROS accumulation co-participate to the
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Fig. 5 Rapamycin induces autophagosomes formation and autophagy resolution. a Cells have been treated for 2, 4, 6, 24, and 48 h with PrP90-
231 (1 μM) in the absence or in the presence of rapamycin (10 nM); 50 μg protein/lane from cytoplasmic fractions were resolved by immunoblotting
using anti-p62 antibody. b P62 immunoreactivity was quantified by densitometry and expressed as ratios on respective β-actin. The treatment with
the peptide increases p62 expression; rapamycin strongly reverts PrP90-231 activity on p62. **P < 0.01 vs. time 0; °°P < 0.01 vs. time-matching PrP90-
231-treated samples. c, d A1 cells were subjected, for 48 h, to trophic factors withdrawal, or treated with PrP90-231 (5 and 10 µM) or rapamycin (10
and 50 nM), and analyzed by TEM for the presence of different vesicular structures. Panel c shows representative images of double-membrane
autophagosomes (early autophagy structures) and single-membrane autophagolysosomes containing partially digested organelles or electron-dense
material (late autophagy vesicles). d The relative amount of autophagosomes and autophagolysosomes was expressed as percent on all vesicular
cytoplasmic structures. All data reported are representative of three independent experiments
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Discussion
Efforts to develop therapies against TSE mainly focused
on preventing PrPC=>PrPSc conversion and the spreading
of PrPSc aggregates. Several molecules, including the anti-
malarial quinacrine and tetracycline antibiotics, have been
tested to prevent the formation, or destabilize PrPC–PrPSc
complex63–66. The outcomes have been so far frustrating
because molecules that prevented prion infectivity in vitro
or delayed clinical onset in experimentally ill animals
failed in humans67,68. Although less challenged, the pre-
vention of PrPSc neurotoxicity is a further pharmacolo-
gical strategy for TSE and other neurodegenerative
PrP90-231
α-tubulin
Fractions L     C      L      C      L      C      L       C  
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52 
PrP90-231 (μM) 0 1 1 1


























PrP90-231       PrP + Rapamycin
C
kDa
Fig. 6 Rapamycin favors autophagy resolution and reduces
PrP90-231 intracellular accumulation. a A1 neurons treated with
PrP90-231 (1 μM, 24 h) in the absence (upper- left panel) or presence
(upper-right panel) of rapamycin (10 nM) were subjected to
immunogold analysis for PrP90-231 aggregates into electron-dense
cytoplasmic vesicles. The number of immunogold-positive spots have
been counted and scored as ratio between the number of gold
particles and vesicle area (gold particles/μm2). b After 24 hours of
treatment with PBS, PrP90-231 1 mM or PrP90-231 in the presence of
rapamycin (10 or 20nM), we separated crude lysosomal (Lys) and
cytosolic (Cyt) fractions by differential centrifugation and performed
immunoblotting using anti PrP90-231 antibody 3F4. The treatment with
PrP90-231 caused a net increase of 16 kDa 3F4-immunioreactive band
into the lysosomal fractions that was significantly and concentration
dependently reduced by the presence of rapamycin. c PrP-
immunoreactive bands in lysosomal fraction were quantified by
densitometry and expressed as ratios on α-tubulin, from three separate
experiments. The treatment with PrP90-231 caused a net increase of 16
kDa 3F4-immunoreactive band into the lysosomal fractions that was
significantly and concentration dependently reduced by the presence
of rapamycin. **P < 0.01 vs. cont; °P < 0.05, and °°P < 0.01 vs. PrP90-231.
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disorders54,69. Indeed, all proteinopathies are character-
ized by aggregation of altered proteins responsible for
neurodegeneration through the formation of neurotoxic
species along with the process of misfolding indepen-
dently from the amino acid sequence3.
Brain deposition of amyloid proteins often associated
with significantly increased autophagy activity, and neu-
rodegeneration is aggravated by conditions that impair
the progression of autophagic flux in neurons, suggesting
that autophagy could represent a mechanism involved in
neuronal loss in neurodegenerative disorders39–41. On the
other hand, pharmacological enhancement of autophagy
can inhibit prion neurotoxicity and infectivity in vitro, and
reduce pathogenicity in animal models of TSE38,70,71,
indicating that boosting cellular mechanisms devoted to
protein clearance provides neuroprotection.
The present work originates from the observation that
intracellular accumulation of neurotoxic PrP90-231 pro-
duces the formation of insoluble and protease-resistant
aggregates associated with impairment of lysosome
membrane permeability51. Here, we determined the nat-
ure of these cytoplasmic inclusions and characterized the
role of lysosomes and autophagy activation as cell
response to PrP90-231 toxicity. PrP90-231 sequence
represents the in vitro counterpart of the amyloidogenic
PrPSc core44 that coexists with full-length protein in TSE
brains, and associates with prion infectivity72 and neuro-
toxicity73. PrP90-231 relevance, as model of neurotoxicity,
Fig. 7 Autophagy enhancement reduces PrP90-231 toxicity on
A1 neurons. a Concentration-response toxicity of PrP90-231 on
A1 cells in standard culture conditions (STD, control) (♦), trophic
factors deprivation (SF) (■) or treatment with rapamycin 10 nM (▲); cell
viability was measured by MTT assay after 72 h of treatment. Cell
culturing in serum-free conditions or treatment with rapamycin
reduced significantly PrP90-231 toxicity. * P < 0.05; **P < 0.01 vs. SF or
rapamycin-treated conditions. b Protective activity of valproic acid
and rapamycin, against PrP90-231 toxicity. Cells have been treated
with rapamycin (10 nM) and valproic acid (1 mM), either alone or in
association, before being exposed to PrP90-231 (1 μM) for 72 h. Values
of cell viability were determined by MTT assay and reported as
percent of untreated samples (Control). Similarly to rapamycin,
valproic acid reduced PrP90-231 cytotoxicity, but no additive effects
were observed when both compounds were simultaneously added.
**P < 0.01 vs. control; °P < 0.05, and °°P < 0.01 vs. PrP90-231. c Lack of
additive protection between trophic factors deprivation and
rapamycin. Cells were divided in the following two subgroups: (1)
grown in standard medium conditions (STD) and (2) deprived of
trophic factors for 24 h (SF). Both series were treated for further 72 h
with PBS (control), PrP90-231 (1 μM), and PrP90-231 (1 μM) plus
rapamycin (10 nM). Cell viability was measured by MTT assay and
compared with their respective controls. MTT assay showed that
under standard growing conditions (left columns), PrP90-231 exerted
significant reduction of cell viability and was strongly antagonized by
rapamycin. Conversely, in condition of trophic factors withdrawal, the
toxicity of PrP90-231 was less pronounced, although still highly
significant, but not affected by treatment with rapamycin. **P < 0.01
vs. control; °°P < 0.01 vs. PrP90-231. All data are reported as mean + /−
SEM of three independent experiments each performed in
quadruplicate
PrP90-231 (μM) - 1 1 1 - - - -
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Fig. 8 Activation of autophagy as specific mechanism of
rapamycin-dependent neuroprotection from PrP90-231 A1
toxicity. a Cells were treated with rapamycin (10 nM), 3-
methyladenine (3-MA, 1 mM) and PrP90-231 (1 μM); cell viability was
measured by MTT assay after 48 h of treatment. The presence of 3-MA
fully prevented rapamycin protection of PrP90-231-induced
neurotoxicity. **P < 0.01 vs. control; °°P < 0.01 vs. PrP90-231. All the
data are reported as mean + /− SEM of three independent
experiments each performed in quadruplicate. b Differential
cytoprotection induced by rapamycin and reduced glutathione (GSH)
against PrP90-231 and hydrogen peroxide (H2O2) neurotoxicity. Cells
were treated with rapamycin (10 nM) or GSH (1 mM), in the presence
of PrP90-231 (1 μM) or H2O2 (200 μM), for 48 h. GSH was added 1 h
before PrP90-231 or H2O2, since it was reported that is slowly
incorporated within the cells62. Cell viability was determined by MTT
assay, and reported as percent on vehicle-treated samples (Control).
PrP90-231 toxicity was strongly reverted by rapamycin, but slightly,
although significantly, by GSH; conversely cell death induced by H2O2
was unmodified by rapamycin and completely abolished by GSH. The
data are reported as mean + /− SEM of three independent
experiments each performed in quadruplicate. **P < 0.01 vs. control; °
P < 0.05, and °°P < 0.01 vs. PrP90-231; XXP < 0.01 vs. H2O2
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resides in the possibility of refold it into a β-sheet-rich
conformation to increases aggregation propensity47.
During the aggregation process, soluble oligomers are
formed as intermediate products50, reproducing struc-
tural and neurotoxic features of oligomers responsible of
other neurodegenerative diseases22. As a neuronal model,
we used the immortalized cell line A1 obtained from
mesencephalic embryonic neurons74, which displayed
significant sensitivity to PrP90-231, different from the SH-
SY5Y neuroblastoma cells that was used in our previous
study51, and were able to survive in conditions of depri-
vation of nutrients (i.e., fetal bovine serum) up to 6 days.
Such resistance, likely sustained by efficient recycling of
intracellular elements through autophagy, indicates that
A1 neurons are a suitable cell model to investigate the
role of proteostasis machinery in modulating the toxicity
of misfolded proteins. TEM analysis supported this
hypothesis since a significant increase in vesicular struc-
tures, belonging to autophagy flux after cell starvation or
treatment with rapamycin was observed. Moreover, ana-
lysis of the expression of autophagosome-related proteins
LC3II produced consonant results, indicating that
autophagosomes content is regulated by starvation or
pharmacological disinhibition. In basal conditions, A1
neurons showed significant sensitivity to PrP90-231
neurotoxicity, with cell death time-dependently asso-
ciated with peptide internalization, increased expression
and cytosolic diffusion of the active Cat-D, and reduction
of mitochondrial membrane potential. Being PrP90-231
partially resistant to proteolysis, its internalization, fol-
lowed by aggregation within lysosomes may impair their
activity and membrane impermeability, turning the
increase of proteolytic activity from a beneficial strategy
for proteostasis into a proapoptotic mechanism51,75. In
this context, the progressive increase of the
autophagosome-linked p62 protein during PrP90-231
treatment shows that the intracellular aggregation of the
peptide stimulates autophagic flux, but leads to the
accumulation of autophagolysomes with impaired reso-
lution ability. Rapamycin co-treatment prevents PrP90-
231-dependent p62 accumulation, indicating that the
incomplete autophagy induced by the peptide can be
pharmacologically unlocked.
In glioma cells, PrPC sustains cell viability by preventing
induction of autophagy, since its gene silencing determine
autophagy-dependent apoptosis76. Thus, altogether, these
data support the notion that, according to cell type and
physiological status, both inhibition and induction of
autophagy can cause cell death and, therefore, autophagy
is a main pharmacological target to control cell viability.
The main result of our study is that different treatments
causing mTOR inhibition strongly reduce PrP90-231
toxicity, suggesting that boosting autophagy promotes
degradation of intralysosomal PrP90-231, preventing
cytosolic diffusion of lysosomal enzymes from damaged
membranes. Importantly, since it was demonstrated that
autophagy may be neuroprotective by clearing cytoplasm
from damaged lysosomes or mitochondria77,78, it is also
reasonable that nutrient deprivation or rapamycin protect
neurons acting downstream to PrP90-231 accumulation,
removing lysosomes filled with PrP90-231. Although we
have no clear evidence of lysosomal or mitochondrial
entrapment into autophagosomes, such intriguing possi-
bility will be further addressed. Importantly, rapamycin-
protective effects were solely mediated by the activation of
autophagy, since the same treatment did not protect cells
from other toxic stimuli (oxygen or nitric oxide radicals,
excitotoxicity), remarking the relevance of the control of
autophagy flux to prevent misfolded protein-related
neuronal death. Importantly, pharmacological protection
from PrP90-231 neurotoxicity has been obtained using
drugs, rapamycin and valproic acid, currently used in
human therapy, and thus beyond being proof-of-principle
tools, they represent a feasible therapeutic approach to be





Mouse monoclonal anti-PrP antibody (clone 3F4) was
purchased from Signet Lab, London, UK. Rabbit poly-
clonal anti-PrP (clone FL 253) and anti-cathepsin-D
(active fragment) were purchased from SantaCruz, CA,
USA. Anti-LC3BI-II and anti-P62 were purchased from
Cell Signaling Technology. Anti-β-actin and anti-α-
tubulin mouse monoclonal antibodies were from Sigma-
Aldrich, Milano, Italy.
Dyes
LysoTrackerTM Red DND-99 and JC-1 were from pur-
chased Molecular Probes, Thermofisher Scientific.
Chemicals
Rapamycin was purchased from Cell Signaling Tech-
nology; 3-methyladenine, valproic acid, and reduced glu-
tathione (GSH) from Sigma-Aldrich, Italy.
Synthesis and refolding of PrP90-231
PrP90-231 was obtained from transformed E. coli and
purified as previously described79. To induce structural
refolding, the protein was incubated for 1 h in NaCl-free
10mM phosphate buffer, pH 7.2 at 53 °C47. This con-
trolled thermal denaturation protocol induces a three-
dimensional refolding of PrP90-231 into a β-sheet-rich
structure, inducing gain of toxicity in vitro47. Thereafter,
the term “PrP90-231” will refer to thermally-refolded
peptide throughout the paper. Cell treatments were
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performed adding the refolded recombinant peptide
directly to the culture medium.
Cell cultures
Murine mes-c-myc A1 (A1) neurons74 were cultured
with RPMI medium (EuroClone, Pero (MI), Italy) sup-
plemented with 100 U/ml penicillin, 100 μg/ml strepto-
mycin, 2 mM glutamine (EuroClone, Pero, Milano, Italy),
5% fetal bovine serum (Gibco-BRL, Milan, Italy), and
maintained at 37 °C in humidified 5% CO2 atmosphere.
Evaluation of cell viability
Phase-contrast microscopy
A1 cells were observed under phase contrast and pho-
tographed using a Leica microscope DM IL, equipped
with ICC50 HD camera.
SYTOX staining
This assay employs the property of green-fluorescent
dye SYTOX green to cross the plasmamembrane and
stain the nucleic acid of dead cells. Briefly, A1 cells were
plated on 12-well cluster dishes at the concentration of
50*103/well and treated with PrP90-231 (100 and 500 nM)
for 48 h. After 15 min of dark-adapted incubation with
SYTOX (ThermoFisher Scientific), 100 nM at r.t., cells
were collected and processed into Cyan ADP Cyto-
fluorimeter (Beckman-Coulter, Brea, CA, USA) using a
488/530 excitation/emission setting; the data were ana-
lyzed with Summit 4.3.1 software (Dakocytomation, Ely,
Cambridgeshire, UK).
MTT reduction assay
Mitochondrial dehydrogenase activity, as index of cell
viability was evaluated measuring the conversion of water-
soluble (3-(4, 5-dimethylthiazol-2-yl)-2,5)-diphenylte-
trazolium bromide (MTT, Sigma-Aldrich, Milano, Italy)
into purple, water-insoluble formazan crystals. MTT
(0.25 mg/ml) was added into culture medium and incu-
bated for 2 h at 37 °C80. Formazan crystals were solubi-
lized with dimethylsulfoxide and the concentration was
measured with ELx800 BioTek colorimeter (optical den-
sity 570 nm).
Trypan blue exclusion test
Cell viability was deduced from the number of Trypan
blue-impermeant cells. Briefly, cells were collected in
phosphate-buffered saline (PBS), pelleted by micro-
centrifugation, and resuspended in serum-free RPMI
growth medium. Cell suspensions were mixed with one
volume of 0.4% Trypan blue solution and immediately
analyzed using the automated cell counter TC20 (Bio-
Rad)54.
Analysis of protein expression
Immunostaining
Cells were seeded in 13mm glass coverslips at 50%
confluence and allowed to grow for 24 h before being
treated according to the experimental protocol. After
treatments, cells were rinsed with PBS, fixed with ice-cold
methanol for 10min, and permeabilized with PBS con-
taining 0,1% triton X-100 for 30 s at r.t. Fixed cells were
then incubated for 15 min. at r.t. in PBS containing 2%
normal goat serum (NGS) to block nonspecific sites and
probed with primary antibodies diluted in PBS–NGS 2%
for 1 h at r.t.81. Immunoreactivity was evidenced by
incubating the coverslips with antisera conjugated with
AlexaFluor 564 (1 h r.t.). Fluorescence was visualized
under fluorescence microscope Leica DM2500 equipped
with Leica DFC310FX camera.
Total cytoplasmic protein extraction
Cells collected in lysis buffer containing TRIS (20 mM,
pH 8), NaCl (137 mM), EDTA (2 mM), glycerol
(10%), NP40 (1%), Na orthovanadate (1 mM), phe-
nylmethylsunfonyl fluoride (PMSF, 1 mM), and the
“Complete” protease inhibitor cocktail (Roche) were
cleared of nuclei and debris by centrifugation to yield
cytoplasmic fractions; protein concentration was mea-
sured by Bradford assay to load equal amounts of proteins
in each sample.
Cytoplasm fractionation
Cells were collected in buffer containing sucrose (250
mM), EDTA (1 mM), HEPES (10 mMpH 7.4), PMSF (1
mM), and the “Complete” protease inhibitor cocktail
(Roche), and homogenized with Teflon-glass potter
(Wheaton Scientific USA) (30 strokes at 4 °C). Protein
concentration was measured by Bradford assay and
samples containing 1mg/ml of total proteins were sub-
jected to centrifugation at 500 rcf for 10 min to clear
cytoplasmic content from nuclei. Lysosomal crude frac-
tions were separated from microsomal and cytosolic
proteins by centrifugation at 20,000 rcf for 20 min.
Immunoblotting
Samples containing equal amounts of proteins were
boiled in Laemmli denaturing buffer, size-fractionated by
SDS-PAGE, and transferred on PVDF 0.2 μm membrane
(Bio-Rad). Membranes were blocked with skim milk
(5% w/vol) in TRIS-buffered saline containing 0.1%
tween-20 (TBS-tween), and probed overnight with pri-
mary antibodies (diluted in TBS-Tween). Immunor-
eactivity was detected with horseradish peroxidase-liked
antisera (GE-Healthcare) and revealed by enhanced che-
miluminescence (ECL, Bio-Rad)82. Protein expression
levels were quantified by densitometric analysis of
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immunoreactivity, using the Chemidoc XRS apparatus
(Bio-Rad Laboratories).
Live cell imaging
Cells were seeded in 35 mm glass bottom petri dishes
(IWAKI) at 50% confluence, and allowed to grow for 24 h
before being treated according to experimental protocol.
After treatments, cells were loaded with viable fluorescent
probes and visualized under inverted fluorescence
microscope (Nikon) equipped with confocal laser scan-
ning system (Bio-Rad MRC1024ES).
Acidic vesicle imaging
Treated cells were incubated with LysoTrackerTM Red
DND-99 (50 nM at 37 °C in complete medium) for 15
min. Cells were then washed twice with medium to
remove excess dye, and observed under confocal micro-
scopy using optical settings for rhodamine (564/590).
Analysis of mitochondrial potential
The viable dye JC-1 exhibits selective tropism for
mitochondria and Abs/Em spectrum that shifts from red
to green along with the decrease of mitochondrial
potential, thus indicating early apoptosis56. Briefly, after
treatments with PrP90-231, cells were incubated with
mitochondrial potential sensor JC-1 (10 μg/ml at 37 °C in
complete medium). After 10 min, cells were washed twice
with medium, to remove excess of JC-1, and observed
under confocal microscopy. Optical settings for rhoda-
mine (564/590) and fluorescein (488/530) were used.
Transmission electron microscopy (TEM)
A1 cells were seeded in glass chamberslides (Lab-Tek,
Nunc, 177380) for 48 h at 37 °C and treated for further 48
h with serum-free medium, PrP90-231 (1 µM), and PrP90-
231 (1µM) with rapamycin (10 nM). Cells were washed
with 0.1M cacodylate buffer in distilled water and fixed in
the same buffer containing 2.5% glutaraldehyde for 1 h at
r.t. Cells were postfixed in 1% osmium tetroxide for 10
min and 1% uranyl acetate for 1 h, dehydrated through a
graded ethanol series embedded in epoxy resin (Poly-Bed;
Polysciences, Inc, Washington, PA, USA) overnight at 60 °
C. Ultrathin sections (50 nm) were observed with a CM10
(Philips, Eindhoven, The Nederlands) without additional
staining. Digital images were taken with Megaview 3 CCd
camera and iTEM software and processed with Adobe
Photoshop CS5.
Immunogold labeling on Tokuyasu cryosections
A1 cells were treated with PrP90-231 (10 µM) with or
without rapamycin (10 nM) for 48 h and then prepared for
cryoimmuno-EM according to Tokuyasu method. Briefly,
cells were fixed in PBS containing 2% paraformaldehyde
and 0.2% glutaraldehyde, for 2 h at rt. Next, cells were
gently scraped and embedded in 12% gelatin. After
overnight infusion with sucrose 2.3M, small squared
blocks were mounted on aluminum pins and frozen in
liquid nitrogen. Ultrathin sections of 60 nm were cut with
Leica UltraCut UCT microtome (Leica Mycrosystems,
Wetzlar, Germany) and immunolabeled with the poly-
clonal anti-prion antibody FL253. Protein A-gold 15 nm
was used to reveal prion protein in extracellular and
intracellular compartments. Gold particles representing
internalized PrP90-231 in intracellular vesicular com-
partments were counted in 10 cellular profiles.
Statistics
The data from cell viability assays and immunoblotting
densitometries were obtained, respectively, from three
independent experiments performed in quadruplicate,
unless otherwise specified. Values were expressed as
mean ± S.E.M. Statistical differences among values (cal-
culated with one-way ANOVA/GraphPad Prism 5.2) were
considered significant and highly significant for P
values ≤ 0.05.
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